$ETTX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Entasis Therapeutics Holdings Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Entasis Therapeutics Holdings Inc.. Get notifications about new insider transactions in Entasis Therapeutics Holdings Inc. for free.
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 02 2021 | ETTX | Entasis Therapeuti ... | Mayer Howard | Director | Grant | A | 0.00 | 22,000 | 0 | 22,000 | 0 to 22 K |
| Apr 02 2021 | ETTX | Entasis Therapeuti ... | Behanna Heather | Director | Grant | A | 0.00 | 22,000 | 0 | 22,000 | 0 to 22 K |
| Apr 02 2021 | ETTX | Entasis Therapeuti ... | Meek David D. | Director | Grant | A | 0.00 | 22,000 | 0 | 22,000 | 0 to 22 K |
| Apr 02 2021 | ETTX | Entasis Therapeuti ... | HASTINGS DAVID C | Director | Grant | A | 0.00 | 22,000 | 0 | 22,000 | 0 to 22 K |
| Jan 19 2021 | ETTX | Entasis Therapeuti ... | Tommasi Ruben | Chief Scientific Of ... | Grant | A | 0.00 | 25,000 | 0 | 47,024 | 22 K to 47 K (+113.51 %) |
| Jan 19 2021 | ETTX | Entasis Therapeuti ... | Ronsheim Matthew | See Remarks | Grant | A | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
| Jan 19 2021 | ETTX | Entasis Therapeuti ... | Perros Manoussos | President & CEO | Grant | A | 0.00 | 79,750 | 0 | 79,750 | 0 to 79.8 K |
| Jan 19 2021 | ETTX | Entasis Therapeuti ... | Keiley Elizabeth M | General Counsel | Grant | A | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
| Jan 19 2021 | ETTX | Entasis Therapeuti ... | Altarac David | Chief Medical Offic ... | Grant | A | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
| Jan 19 2021 | ETTX | Entasis Therapeuti ... | Mueller John Patrick | Chief Development O ... | Grant | A | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
| Oct 06 2020 | ETTX | Entasis Therapeuti ... | Meek David D. | Director | Option Exercise | A | 2.98 | 11,000 | 32,780 | 11,000 | |
| Oct 06 2020 | ETTX | Entasis Therapeuti ... | HASTINGS DAVID C | Director | Option Exercise | A | 2.98 | 11,000 | 32,780 | 11,000 | |
| Oct 06 2020 | ETTX | Entasis Therapeuti ... | Behanna Heather | Director | Option Exercise | A | 2.98 | 11,000 | 32,780 | 11,000 | |
| Oct 06 2020 | ETTX | Entasis Therapeuti ... | Mayer Howard | Director | Option Exercise | A | 2.98 | 11,000 | 32,780 | 11,000 | |
| Sep 01 2020 | ETTX | Entasis Therapeuti ... | Innoviva, Inc. | 10% Owner | Option Exercise | P | 2.68 | 4,672,897 | 12,499,999 | 18,672,897 | |
| Sep 01 2020 | ETTX | Entasis Therapeuti ... | Innoviva, Inc. | 10% Owner | Buy | P | 2.68 | 4,672,897 | 12,499,999 | 18,672,897 | 14 M to 18.7 M (+33.38 %) |
| Jun 12 2020 | ETTX | Entasis Therapeuti ... | Innoviva, Inc. | 10% Owner | Option Exercise | P | 2.50 | 12,677,490 | 31,693,725 | 14,000,000 | |
| Jun 12 2020 | ETTX | Entasis Therapeuti ... | Innoviva, Inc. | 10% Owner | Buy | P | 2.50 | 12,677,490 | 31,693,725 | 14,000,000 | 1.3 M to 14 M (+958.59 %) |
| Jan 27 2020 | ETTX | Entasis Therapeuti ... | Altarac David | Chief Medical Offic ... | Option Exercise | A | 4.94 | 50,000 | 247,000 | 50,000 | |
| Jan 27 2020 | ETTX | Entasis Therapeuti ... | Perros Manoussos | President and CEO | Option Exercise | A | 4.94 | 145,000 | 716,300 | 145,000 | |
| Jan 27 2020 | ETTX | Entasis Therapeuti ... | Kimble Eric Wilson | Chief Commercial Of ... | Option Exercise | A | 4.94 | 50,000 | 247,000 | 50,000 | |
| Jan 27 2020 | ETTX | Entasis Therapeuti ... | Keiley Elizabeth M | General Counsel | Option Exercise | A | 4.94 | 50,000 | 247,000 | 50,000 | |
| Jan 27 2020 | ETTX | Entasis Therapeuti ... | Gutch Michael | Chief Fin. and Bus. ... | Option Exercise | A | 4.94 | 50,000 | 247,000 | 50,000 | |
| Jan 27 2020 | ETTX | Entasis Therapeuti ... | Tommasi Ruben | Chief Scientific Of ... | Option Exercise | A | 4.94 | 50,000 | 247,000 | 50,000 | |
| Jan 27 2020 | ETTX | Entasis Therapeuti ... | Mueller John Patrick | Chief Development O ... | Option Exercise | A | 4.94 | 50,000 | 247,000 | 50,000 | |
| Jan 13 2020 | ETTX | Entasis Therapeuti ... | Frazier Life Sciences VIII, L. ... | 10% Owner | Sell | S | 5.00 | 50,000 | 250,010 | 1,299,953 | 1.3 M to 1.3 M (-3.70 %) |
| Nov 06 2019 | ETTX | Entasis Therapeuti ... | Altarac David | Chief Medical Offic ... | Option Exercise | A | 5.70 | 120,000 | 684,000 | 120,000 | |
| Aug 06 2019 | ETTX | Entasis Therapeuti ... | Mayer Howard | Director | Option Exercise | A | 6.44 | 15,000 | 96,600 | 15,000 | |
| Jun 21 2019 | ETTX | Entasis Therapeuti ... | Meek David D. | Director | Option Exercise | A | 6.12 | 15,000 | 91,800 | 15,000 | |
| Jun 21 2019 | ETTX | Entasis Therapeuti ... | Meek David D. | Director | Option Exercise | A | 6.12 | 7,500 | 45,900 | 7,500 | |
| Jun 21 2019 | ETTX | Entasis Therapeuti ... | HASTINGS DAVID C | Director | Option Exercise | A | 6.12 | 7,500 | 45,900 | 7,500 | |
| Jun 21 2019 | ETTX | Entasis Therapeuti ... | Norden Gregory | Director | Option Exercise | A | 6.12 | 7,500 | 45,900 | 7,500 | |
| Jun 21 2019 | ETTX | Entasis Therapeuti ... | Behanna Heather | Director | Option Exercise | A | 6.12 | 7,500 | 45,900 | 7,500 | |
| Jun 21 2019 | ETTX | Entasis Therapeuti ... | Preston Heather | Director | Option Exercise | A | 6.12 | 7,500 | 45,900 | 7,500 | |
| Jun 21 2019 | ETTX | Entasis Therapeuti ... | GALAKATOS NICHOLAS | Director | Option Exercise | A | 6.12 | 7,500 | 45,900 | 7,500 | |
| Jan 22 2019 | ETTX | Entasis Therapeuti ... | Topper James N | Director | Option Exercise | A | 5.66 | 15,000 | 84,900 | 15,000 | |
| Jan 22 2019 | ETTX | Entasis Therapeuti ... | Tommasi Ruben | Chief Scientific Of ... | Option Exercise | A | 5.66 | 56,500 | 319,790 | 56,500 | |
| Jan 22 2019 | ETTX | Entasis Therapeuti ... | Perros Manoussos | President and CEO | Option Exercise | A | 5.66 | 123,500 | 699,010 | 123,500 | |
| Jan 22 2019 | ETTX | Entasis Therapeuti ... | Norden Gregory | Director | Option Exercise | A | 5.66 | 15,000 | 84,900 | 15,000 | |
| Jan 22 2019 | ETTX | Entasis Therapeuti ... | Mueller John Patrick | Chief Development O ... | Option Exercise | A | 5.66 | 56,500 | 319,790 | 56,500 | |
| Jan 22 2019 | ETTX | Entasis Therapeuti ... | Isaacs Robin | Chief Medical Offic ... | Option Exercise | A | 5.66 | 56,500 | 319,790 | 56,500 | |
| Jan 22 2019 | ETTX | Entasis Therapeuti ... | HASTINGS DAVID C | Director | Option Exercise | A | 5.66 | 15,000 | 84,900 | 15,000 | |
| Jan 22 2019 | ETTX | Entasis Therapeuti ... | Gutch Michael | CFO and Chief Busin ... | Option Exercise | A | 5.66 | 56,500 | 319,790 | 56,500 | |
| Jan 22 2019 | ETTX | Entasis Therapeuti ... | GALAKATOS NICHOLAS | Director | Option Exercise | A | 5.66 | 15,000 | 84,900 | 15,000 | |
| Jan 22 2019 | ETTX | Entasis Therapeuti ... | Behanna Heather | Director | Option Exercise | A | 5.66 | 15,000 | 84,900 | 15,000 | |
| Dec 26 2018 | ETTX | Entasis Therapeuti ... | Tommasi Ruben | Chief Scientific Of ... | Option Exercise | M | 3.11 | 10,236 | 31,834 | 24,858 | |
| Dec 26 2018 | ETTX | Entasis Therapeuti ... | Tommasi Ruben | Chief Scientific Of ... | Option Exercise | M | 3.11 | 10,236 | 31,834 | 24,858 | |
| Dec 26 2018 | ETTX | Entasis Therapeuti ... | Tommasi Ruben | Chief Scientific Of ... | Option Exercise | M | 3.74 | 11,788 | 44,087 | 6,465 | |
| Dec 26 2018 | ETTX | Entasis Therapeuti ... | Tommasi Ruben | Chief Scientific Of ... | Option Exercise | M | 3.74 | 11,788 | 44,087 | 6,465 | |
| Dec 26 2018 | ETTX | Entasis Therapeuti ... | Tommasi Ruben | Chief Scientific Of ... | Buy | M | 3.11 | 10,236 | 31,834 | 22,024 | 11.8 K to 22 K (+86.83 %) |
| Dec 26 2018 | ETTX | Entasis Therapeuti ... | Tommasi Ruben | Chief Scientific Of ... | Buy | M | 3.11 | 10,236 | 31,834 | 22,024 | 11.8 K to 22 K (+86.83 %) |
| Dec 26 2018 | ETTX | Entasis Therapeuti ... | Tommasi Ruben | Chief Scientific Of ... | Buy | M | 3.74 | 11,788 | 44,087 | 11,788 | 0 to 11.8 K |
| Dec 26 2018 | ETTX | Entasis Therapeuti ... | Tommasi Ruben | Chief Scientific Of ... | Buy | M | 3.74 | 11,788 | 44,087 | 11,788 | 0 to 11.8 K |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Topper James N | Director | Option Exercise | C | 0.00 | 6,651,574 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Topper James N | Director | Option Exercise | C | 0.00 | 5,212,833 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Topper James N | Director | Option Exercise | C | 0.00 | 7,000,000 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Topper James N | Director | Buy | P | 15.00 | 375,887 | 5,638,305 | 1,349,953 | 974.1 K to 1.3 M (+38.59 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Topper James N | Director | Buy | C | 0.00 | 320,898 | 0 | 974,066 | 653.2 K to 974.1 K (+49.13 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Topper James N | Director | Buy | C | 0.00 | 251,487 | 0 | 589,194 | 337.7 K to 589.2 K (+74.47 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Topper James N | Director | Buy | C | 0.00 | 337,707 | 0 | 337,707 | 0 to 337.7 K |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Sofinnova Venture Partners IX, ... | 10% Owner | Option Exercise | C | 0.00 | 9,502,249 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Sofinnova Venture Partners IX, ... | 10% Owner | Option Exercise | C | 0.00 | 7,446,904 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Sofinnova Venture Partners IX, ... | 10% Owner | Buy | P | 15.00 | 337,724 | 5,065,860 | 1,180,178 | 842.5 K to 1.2 M (+40.09 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Sofinnova Venture Partners IX, ... | 10% Owner | Buy | C | 0.00 | 458,425 | 0 | 842,454 | 384 K to 842.5 K (+119.37 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Sofinnova Venture Partners IX, ... | 10% Owner | Buy | C | 0.00 | 359,267 | 0 | 359,267 | 0 to 359.3 K |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Preston Heather | Director | Option Exercise | C | 0.00 | 9,502,249 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Preston Heather | Director | Option Exercise | C | 0.00 | 7,446,904 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Preston Heather | Director | Buy | P | 15.00 | 337,724 | 5,065,860 | 1,180,178 | 842.5 K to 1.2 M (+40.09 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Preston Heather | Director | Buy | C | 0.00 | 458,425 | 0 | 842,454 | 384 K to 842.5 K (+119.37 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Preston Heather | Director | Buy | C | 0.00 | 359,267 | 0 | 359,267 | 0 to 359.3 K |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Pivotal bioVenture Partners Fu ... | 10% Owner | Option Exercise | C | 0.00 | 9,502,249 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Pivotal bioVenture Partners Fu ... | 10% Owner | Option Exercise | C | 0.00 | 7,446,904 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Pivotal bioVenture Partners Fu ... | 10% Owner | Buy | P | 15.00 | 337,724 | 5,065,860 | 1,180,178 | 842.5 K to 1.2 M (+40.09 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Pivotal bioVenture Partners Fu ... | 10% Owner | Buy | C | 0.00 | 458,425 | 0 | 842,454 | 384 K to 842.5 K (+119.37 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Pivotal bioVenture Partners Fu ... | 10% Owner | Buy | C | 0.00 | 359,267 | 0 | 359,267 | 0 to 359.3 K |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | GALAKATOS NICHOLAS | Director | Option Exercise | C | 0.00 | 8,552,024 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | GALAKATOS NICHOLAS | Director | Option Exercise | C | 0.00 | 6,702,213 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | GALAKATOS NICHOLAS | Director | Option Exercise | C | 0.00 | 7,500,000 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | GALAKATOS NICHOLAS | Director | Buy | P | 15.00 | 453,395 | 6,800,925 | 1,623,405 | 1.2 M to 1.6 M (+38.75 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | GALAKATOS NICHOLAS | Director | Buy | C | 0.00 | 412,583 | 0 | 1,170,010 | 757.4 K to 1.2 M (+54.47 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | GALAKATOS NICHOLAS | Director | Buy | C | 0.00 | 323,341 | 0 | 685,170 | 361.8 K to 685.2 K (+89.36 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | GALAKATOS NICHOLAS | Director | Buy | C | 0.00 | 361,829 | 0 | 361,829 | 0 to 361.8 K |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Frazier Life Sciences VIII, L. ... | 10% Owner | Option Exercise | C | 0.00 | 6,651,574 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Frazier Life Sciences VIII, L. ... | 10% Owner | Option Exercise | C | 0.00 | 5,212,833 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Frazier Life Sciences VIII, L. ... | 10% Owner | Option Exercise | C | 0.00 | 7,000,000 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Frazier Life Sciences VIII, L. ... | 10% Owner | Buy | P | 15.00 | 375,887 | 5,638,305 | 1,349,953 | 974.1 K to 1.3 M (+38.59 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Frazier Life Sciences VIII, L. ... | 10% Owner | Buy | C | 0.00 | 320,898 | 0 | 974,066 | 653.2 K to 974.1 K (+49.13 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Frazier Life Sciences VIII, L. ... | 10% Owner | Buy | C | 0.00 | 251,487 | 0 | 589,194 | 337.7 K to 589.2 K (+74.47 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Frazier Life Sciences VIII, L. ... | 10% Owner | Buy | C | 0.00 | 337,707 | 0 | 337,707 | 0 to 337.7 K |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Clarus Lifesciences III, L.P. | 10% Owner | Option Exercise | C | 0.00 | 8,552,024 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Clarus Lifesciences III, L.P. | 10% Owner | Option Exercise | C | 0.00 | 6,702,213 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Clarus Lifesciences III, L.P. | 10% Owner | Option Exercise | C | 0.00 | 7,500,000 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Clarus Lifesciences III, L.P. | 10% Owner | Buy | P | 15.00 | 453,395 | 6,800,925 | 1,623,405 | 1.2 M to 1.6 M (+38.75 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Clarus Lifesciences III, L.P. | 10% Owner | Buy | C | 0.00 | 412,583 | 0 | 1,170,010 | 757.4 K to 1.2 M (+54.47 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Clarus Lifesciences III, L.P. | 10% Owner | Buy | C | 0.00 | 323,341 | 0 | 685,170 | 361.8 K to 685.2 K (+89.36 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | Clarus Lifesciences III, L.P. | 10% Owner | Buy | C | 0.00 | 361,829 | 0 | 361,829 | 0 to 361.8 K |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | ASTRAZENECA PLC | 10% Owner | Option Exercise | C | 0.00 | 33,499,900 | 0 | 0 | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | ASTRAZENECA PLC | 10% Owner | Buy | P | 15.00 | 246,666 | 3,699,990 | 2,164,855 | 1.9 M to 2.2 M (+12.86 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | ASTRAZENECA PLC | 10% Owner | Buy | C | 0.00 | 1,918,185 | 0 | 1,918,189 | 4 to 1.9 M (+47,954,625.00 %) |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | TPG Group Holdings (SBS) Advis ... | Option Exercise | C | 0.00 | 15,254,237 | 0 | 0 | ||
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | TPG Group Holdings (SBS) Advis ... | Buy | P | 15.00 | 262,539 | 3,938,085 | 1,020,748 | 758.2 K to 1 M (+34.63 %) | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | TPG Group Holdings (SBS) Advis ... | Buy | J | 0.00 | 22,285 | 0 | 758,209 | 735.9 K to 758.2 K (+3.03 %) | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | TPG Group Holdings (SBS) Advis ... | Buy | C | 0.00 | 735,924 | 0 | 735,924 | 0 to 735.9 K | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | TPG Group Holdings (SBS) Advis ... | Option Exercise | C | 0.00 | 15,254,237 | 0 | 0 | ||
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | TPG Group Holdings (SBS) Advis ... | Buy | P | 15.00 | 262,539 | 3,938,085 | 1,020,748 | 758.2 K to 1 M (+34.63 %) | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | TPG Group Holdings (SBS) Advis ... | Buy | J | 0.00 | 22,285 | 0 | 758,209 | 735.9 K to 758.2 K (+3.03 %) | |
| Oct 02 2018 | ETTX | Entasis Therapeuti ... | TPG Group Holdings (SBS) Advis ... | Buy | C | 0.00 | 735,924 | 0 | 735,924 | 0 to 735.9 K | |
| Oct 01 2018 | ETTX | Entasis Therapeuti ... | Novo Holdings A/S | 10% Owner | Option Exercise | C | 0.00 | 14,237,288 | 0 | 0 | |
| Oct 01 2018 | ETTX | Entasis Therapeuti ... | Novo Holdings A/S | 10% Owner | Option Exercise | C | 0.00 | 7,000,000 | 0 | 0 | |
| Oct 01 2018 | ETTX | Entasis Therapeuti ... | Novo Holdings A/S | 10% Owner | Buy | P | 15.00 | 1,089,835 | 16,347,525 | 2,181,843 | 1.1 M to 2.2 M (+99.80 %) |
| Oct 01 2018 | ETTX | Entasis Therapeuti ... | Novo Holdings A/S | 10% Owner | Buy | C | 0.00 | 1,092,008 | 0 | 1,092,008 | 0 to 1.1 M |
| Sep 27 2018 | ETTX | Entasis Therapeuti ... | Perros Manoussos | President and CEO | Option Exercise | A | 15.00 | 79,698 | 1,195,470 | 79,698 | |
| Sep 27 2018 | ETTX | Entasis Therapeuti ... | Tommasi Ruben | Chief Scientific Of ... | Option Exercise | A | 15.00 | 50,411 | 756,165 | 50,411 | |
| Sep 27 2018 | ETTX | Entasis Therapeuti ... | Mueller John Patrick | Chief Development O ... | Option Exercise | A | 15.00 | 7,265 | 108,975 | 7,265 | |
| Sep 27 2018 | ETTX | Entasis Therapeuti ... | Isaacs Robin | Chief Medical Offic ... | Option Exercise | A | 15.00 | 32,116 | 481,740 | 32,116 | |
| Sep 27 2018 | ETTX | Entasis Therapeuti ... | Gutch Michael | CFO and Chief Busin ... | Option Exercise | A | 15.00 | 15,956 | 239,340 | 15,956 |
Page: 1